A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Guérin in the treatment of bladder cancer

Biomaterials

Volumn 34, Issue 38, 2013, Pages 10258-10266

  Zhang, Dong ^a   Sun, Peng ^a   Li, Peng ^a   Xue, Aibing ^a   Zhang, Xiaokai ^b   Zhang, Haiyang ^a,c   Jin, Xunbo ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG NORMAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bacillus Calmette Gu rin; Chitosan; Intravesical drug delivery; Intravesical instillation; Magnetic nanoparticle; Thermosensitive hydrogel

Indexed keywords

ANTI-TUMOR EFFICACY; APPLIED MAGNETIC FIELDS; INJECTABLE HYDROGELS; INTRAVESICAL INSTILLATION; MAGNETIC CHITOSAN; MAGNETIC NANO-PARTICLES; MAGNETIC RESPONSE; THERMO-SENSITIVE HYDROGEL;

BACTERIOLOGY; CHITOSAN; DRUG DELIVERY; GELATION; NANOPARTICLES; PHOSPHOLIPIDS; SCANNING ELECTRON MICROSCOPY;

HYDROGELS;

BCG VACCINE; CHITOSAN; GLYCEROL 2 PHOSPHATE; IRON OXIDE; MAGNETIC NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BODY TEMPERATURE; CANCER CHEMOTHERAPY; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FROZEN SECTION; GELATION; HEAT SENSITIVITY; HYDROGEL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MAGNETIC FIELD; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; ROOM TEMPERATURE; SCANNING ELECTRON MICROSCOPE; SOLUTION AND SOLUBILITY;

MYCOBACTERIUM BOVIS BCG;

BACILLUS CALMETTE-GUÉRIN; CHITOSAN; INTRAVESICAL DRUG DELIVERY; INTRAVESICAL INSTILLATION; MAGNETIC NANOPARTICLE; THERMOSENSITIVE HYDROGEL;

ANIMALS; BCG VACCINE; CHITOSAN; FEMALE; HYDROGEL; IMMUNOHISTOCHEMISTRY; MICROSCOPY, ELECTRON, SCANNING; RATS; TEMPERATURE; URINARY BLADDER NEOPLASMS;

EID: 84885376077     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.027     Document Type: Article

References (40)

1. Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. JUrol 1976, 116:180-183.
2. Babjuk M., Burger M., Zigeuner R., Shariat S.F., van Rhijn B.W., Comperat E., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013, 64:639-653.
3. Zuiverloon T.C., Nieuweboer A.J., Vekony H., Kirkels W.J., Bangma C.H., Zwarthoff E.C. Markers predicting response to Bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 2012, 61:128-145.
4. Kresowik T.P., Griffith T.S. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 2009, 1:281-288.
5. Kawai K., Miyazaki J., Joraku A., Nishiyama H., Akaza H. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 2013, 104:22-27.
6. Morales A. Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent. Expert Opin Investig Drugs 2008, 17:1067-1073.
7. Liu W., O'Donnell M.A., Chen X., Han R., Luo Y. Recombinant Bacillus Calmette-Guerin (BCG) expressing interferon-alpha 2b enhances human mononuclear cell cytotoxicity against bladder cancer cell lines invitro. Cancer Immunol Immunother 2009, 58:1647-1655.
8. Tyagi P., Li Z., Chancellor M., De Groat W.C., Yoshimura N., Huang L. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res 2004, 21:832-837.
9. Tyagi P., Tyagi S., Kaufman J., Huang L., de Miguel F. Local drug delivery to bladder using technology innovations. Urol Clin North Am 2006, 33:519-530.
10. Shi W., Ji Y., Zhang X., Shu S., Wu Z. Characterization of ph- and thermosensitive hydrogel as a vehicle for controlled protein delivery. JPharm Sci 2011, 100:886-895.
11. Niranjan R., Koushik C., Saravanan S., Moorthi A., Vairamani M., Selvamurugan N. Anovel injectable temperature-sensitive zinc doped chitosan/beta-glycerophosphate hydrogel for bone tissue engineering. Int J Biol Macromol 2013, 54:24-29.
12. Gong C., Qi T., Wei X., Qu Y., Wu Q., Luo F., et al. Thermosensitive polymeric hydrogels as drug delivery systems. Curr Med Chem 2013, 20:79-94.
13. Wang W., Zhang P., Shan W., Gao J., Liang W. Anovel chitosan-based thermosensitive hydrogel containing doxorubicin liposomes for topical cancer therapy. JBiomater Sci Polym Ed 2013, 24:1649-1659.
14. Leakakos T., Ji C., Lawson G., Peterson C., Goodwin S. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol 2003, 51:445-450.
15. Chen D., Tang Q., Li X., Zhou X., Zang J., Xue W.Q., et al. Biocompatibility of magnetic Fe3O4 nanoparticles and their cytotoxic effect on MCF-7 cells. Int J Nanomed 2012, 7:4973-4982.
16. GuhaSarkar S., Banerjee R. Intravesical drug delivery: challenges, current status, opportunities and novel strategies. JControl Release 2010, 148:147-159.
17. Peng Q., Sun X., Gong T., Wu C.Y., Zhang T., Tan J., et al. Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin. Acta Biomater 2013, 9:5063-5069.
18. Parada B., Reis F., Figueiredo A., Nunes P., Teixeira-Lemos E., Garrido P., et al. Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. BJU Int 2011, 107:135-143.
19. Delto J.C., Kobayashi T., Benson M., McKiernan J., Abate-Shen C. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget 2013, 4:269-276.
20. Li K., Chen B., Xu L., Feng J., Xia G., Cheng J., et al. Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells invitro and invivo. Int J Nanomed 2013, 8:1867-1877.
21. Zaharoff D.A., Hoffman B.S., Hooper H.B., Benjamin C.J., Khurana K.K., Hance K.W., et al. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res 2009, 69:6192-6199.
22. Dovedi S.J., Kirby J.A., Davies B.R., Leung H., Kelly J.D. Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Eur Urol 2008, 54:621-630.
23. Zhou D., Zhang G., Gan Z. C(RGDfK) decorated micellar drug delivery system for intravesical instilled chemotherapy of superficial bladder cancer. JControl Release 2013, 169:204-210.
24. Kean T., Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 2010, 62:3-11.
25. Hastings C.L., Kelly H.M., Murphy M.J., Barry F.P., O'Brien F.J., Duffy G.P. Development of a thermoresponsive chitosan gel combined with human mesenchymal stem cells and desferrioxamine as a multimodal pro-angiogenic therapeutic for the treatment of critical limb ischaemia. JControl Release 2012, 161:73-80.
26. Wang W., Zhang P., Shan W., Gao J., Liang W. Anovel chitosan-based thermosensitive hydrogel containing doxorubicin liposomes for topical cancer therapy. JBiomater Sci Polym Ed 2013, 24:1649-1659.
27. Bae W.K., Park M.S., Lee J.H., Hwang J.E., Shim H.J., Cho S.H., et al. Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer. Biomaterials 2013, 34:1433-1441.
28. Wu Y., Wei W., Zhou M., Wang Y., Wu J., Ma G., et al. Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization. Biomaterials 2012, 33:2351-2360.
29. Richterstetter M., Wullich B., Amann K., Haeberle L., Engehausen D.G., Goebell P.J., et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int 2012, 110:76-79.
30. Sinn H.W., Elzey B.D., Jensen R.J., Zhao X., Zhao W., Ratliff T.L. The fibronectin attachment protein of Bacillus Calmette-Guerin (BCG) mediates antitumor activity. Cancer Immunol Immunother 2008, 57:573-579.
31. Eroǧlu M., Irmak S., Acar A., Denkbaş E.B. Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer. Int J Pharm 2002, 235:51-59.
32. Rosenthal R., Günzel D., Finger C., Krug S.M., Richter J.F., Schulzke J.-D., et al. The effect of chitosan on transcellular and paracellular mechanisms in the intestinal epithelial barrier. Biomaterials 2012, 33:2791-2800.
33. Verheul R.J., Amidi M., van Steenbergen M.J., van Riet E., Jiskoot W., Hennink W.E. Influence of the degree of acetylation on the enzymatic degradation and invitro biological properties of trimethylated chitosans. Biomaterials 2009, 30:3129-3135.
34. Kobayashi T., Fukushima K., Sannan T., Saito N., Takiguchi Y., Sato Y., et al. Evaluation of the effectiveness and safety of chitosan derivatives as adjuvants for intranasal vaccines. Viral Immunol 2013, 26:133-142.
35. Shen Z.J., Wang Y., Ding G.Q., Pan C.W., Zheng R.M. Study on enhancement of fibronectin-mediated Bacillus Calmette-Guerin attachment to urinary bladder wall in rabbits. World J Urol 2007, 25:525-529.
36. Yoneyama T., Ohyama C., Imai A., Ishimura H., Hagisawa S., Iwabuchi I., et al. Low-dose instillation therapy with Bacille Calmette-Guerin Tokyo 172 strain after transurethral resection: historical cohort study. Urology 2008, 71:1161-1165.
37. Irie A., Uchida T., Yamashita H., Matsumoto K., Satoh T., Koh H., et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose Bacillus Calmette-Guerin for superficial bladder cancer recurrence. Int J Urol 2003, 10:183-189.
38. Martinez-Pineiro J.A., Flores N., Isorna S., Solsona E., Sebastian J.L., Pertusa C., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical Bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002, 89:671-680.
39. Ta H.T., Han H., Larson I., Dass C.R., Dunstan D.E. Chitosan-dibasic orthophosphate hydrogel: a potential drug delivery system. Int J Pharm 2009, 371:134-141.
40. Yeo Y., Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res 2004, 27:1-12.